| Ytd | -60.00% | |
| 1y | -77.50% |
| Open | 1.53 | Prev Close | 1.47 | Low | 1.43 | High | 1.53 | Mkt Cap | 8.74M |
| Vol | 20.45K | Avg Vol | 52.14K | EPS | -2.98 | P/E | -0.48 | Forward P/E | -0.13 |
| Beta | 1.04 | Short Ratio | 0.31 | Inst. Own | 11.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.59 | 200-d Avg | 2.48 | 1yr Est | 64.50 |
NCNA News
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte
Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular s
Gainers VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-m
NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceu
EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or
Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clear
U.S. stock futures fall around 250 points on Monday. ASTS shares drop 13.5% after satellite placed i
US stock futures lower, Dow falls 200 points. Unusual Machines Inc announces public offering, shares
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resista
Dow futures up 200 points, ClearPoint Neuro (CLPT) stock falls after wider-than-expected quarterly l
EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or
Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety
Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NU
EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or
EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or
EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients w
EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or
EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or
EDINBURGH, United Kingdom, July 11, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or
Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 I
